IZH2 Antibody

What is EZH2 and what cellular functions does it regulate?

EZH2 (Enhancer of zeste homolog 2) is a histone methyltransferase that catalyzes the tri-methylation of histone H3 at lysine 27 (H3K27me3), a critical epigenetic mark associated with gene silencing . As a core catalytic component of the Polycomb Repressive Complex 2 (PRC2), EZH2 plays a central role in epigenetic regulation of gene expression.

The PRC2/EED-EZH2 complex can serve as a recruiting platform for DNA methyltransferases, which establishes an important link between two distinct epigenetic repression systems . Through this mechanism, EZH2 contributes to:

• Transcriptional silencing of target genes

• Cell cycle regulation

• Maintenance of cellular identity

• Embryonic development

• Cancer progression when dysregulated

EZH2 is expressed in many tissues throughout the body but has been found to be overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma, and testis .

What are the technical specifications of commercially available EZH2 antibodies?

Based on the available research data, EZH2 antibodies present several key specifications that researchers should consider when selecting the appropriate reagent for their experiments:

When performing Western blot analysis, researchers should expect to detect EZH2 at approximately 80-85 kDa, though some antibodies may detect additional bands at 100 kDa depending on post-translational modifications or splice variants .

What validation methods should be used to confirm EZH2 antibody specificity?

Validating antibody specificity is crucial for generating reliable experimental results. For EZH2 antibodies, researchers should implement the following validation methods:

• Western Blot Analysis: Confirm single band detection at the expected molecular weight (approximately 80 kDa) using positive control cell lines such as HeLa, Jurkat, or mouse spleen tissue .

• Knockout/Knockdown Controls: Compare antibody detection in wild-type cells versus those with genetically reduced EZH2 expression. For example, siRNA-mediated knockdown of interacting partners like SIRT1 has been shown to affect EZH2 protein detection patterns .

• Cross-Reactivity Testing: Verify antibody performance across multiple species if multi-species reactivity is claimed. Available data confirms detection of EZH2 in human cell lines (HeLa, Jurkat) and mouse tissues .

• Functional Assays: Confirm that the antibody can detect changes in EZH2 expression or activity after treatment with EZH2 inhibitors such as GSK126 or EPZ6438 .

• Chromatin Immunoprecipitation: For ChIP applications, validate by confirming enrichment at known EZH2 target genes followed by qPCR or sequencing.

What cell lines and tissue samples are optimal for studying EZH2 expression?

Based on research findings, the following biological samples have demonstrated reliable EZH2 expression and are recommended for experimental studies:

Cell Lines:

• HeLa human cervical epithelial carcinoma cell line

• Jurkat human acute T cell leukemia cell line

• A549, HCC15, HCC95, and H520 non-small cell lung cancer cell lines

Tissue Samples:

• Mouse spleen tissue

• Human lung squamous cell carcinoma tissue samples, which have been successfully used for patient-derived tumoroid (PDT) culture development

For researchers studying EZH2 in cancer contexts, 3D patient-derived tumoroid cultures have been shown to retain the epigenetic state of in vivo tumors more effectively than traditional 2D cultures, potentially providing more translatable results .

How can EZH2 antibodies be used to study the impact of EZH2 inhibition on MHC expression?

EZH2 inhibition has been shown to significantly impact Major Histocompatibility Complex (MHC) expression, particularly when combined with interferon-gamma (IFNγ) treatment. Researchers can use EZH2 antibodies in conjunction with the following experimental approach:

• Treatment Protocol Design:

  • Treat cells with EZH2 inhibitors (GSK126 or EPZ6438) for 5-9 days

  • Add IFNγ for the final 2 days of treatment

  • Include appropriate controls: vehicle only, EZH2 inhibitor only, and IFNγ only

• Multilevel Analysis Approach:

  a) Transcriptional Analysis:

  • Perform RT-qPCR to measure mRNA expression of:

    • MHC Class I genes: B2M, HLA-A

    • MHC Class II genes: CIITA, HLA-DRA

    • Other immunomodulatory genes: CD274 (PD-L1), NGFR

  b) Protein Expression Analysis:

  • Flow cytometry to measure cell surface expression of:

    • MHC Class I: HLA-A,B,C

    • MHC Class II: HLA-DR

    • Checkpoint molecules: PD-L1

  c) Western Blotting:

  • Confirm changes in B2M and HLA-DR,DQ,DP

  • Verify EZH2 inhibition efficacy by measuring H3K27me3 levels

Research has demonstrated that combined EZH2 inhibition and IFNγ treatment produces a stepwise increase in MHC expression, with the highest levels observed in co-treated cultures, particularly for MHC Class II proteins like HLA-DR .

What methodological considerations are important when using EZH2 antibodies in ChIP-seq experiments?

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) using EZH2 antibodies provides critical insights into the epigenetic regulation mechanisms. Based on research protocols, the following methodological considerations are essential:

• Experimental Design:

  • Include treatments that modify EZH2 activity (e.g., EZH2 inhibitors)

  • Include biological replicates

  • Plan for multiple histone mark analyses in parallel (H3K27me3, H3K27ac, H3K4me3) to understand the complete epigenetic landscape

• ChIP Protocol Optimization:

  • Crosslinking conditions must be optimized for EZH2 binding

  • Sonication parameters should be adjusted to achieve 200-500bp DNA fragments

  • Include input controls and IgG controls

  • For 3D cultures or tumoroids, additional disaggregation steps may be required

• Data Analysis Framework:

  • Assess changes in H3K27me3 peak distribution after EZH2 inhibition

  • Correlate loss of H3K27me3 with gain of activating marks (H3K27ac, H3K4me3)

  • Integrate ChIP-seq with RNA-seq data to identify direct transcriptional targets

  • Perform gene set enrichment analysis to identify affected pathways

Research has identified several patterns of epigenetic regulation following EZH2 inhibition:

• Complete loss of H3K27me3 at specific loci (e.g., MHC Class II genes)

• Reduction of IFNγ-induced H3K27me3 at pro-inflammatory gene clusters (e.g., CXCL9/10/11)

• Gain of H3K27ac at loci that lost H3K27me3, indicating transcriptional activation

How do results from EZH2 antibody-based experiments differ between 2D cell cultures and 3D tumoroid models?

The research environment significantly impacts EZH2 antibody-based experimental outcomes. Key differences between 2D and 3D models include:

Methodological adaptations for 3D cultures:

• Longer treatment durations (9 days for 3D vs. 5 days for 2D)

• Modified sample processing for flow cytometry and Western blot

• Additional disaggregation steps for ChIP-seq and RNA extraction

The research indicates that patient-derived tumoroid (PDT) cultures retain the epigenetic state of in vivo tumors more effectively than traditional 2D cultures, potentially providing more translatable results for clinical applications .

What are the key regulatory mechanisms underlying EZH2-mediated suppression of immune response genes?

EZH2 antibody-based studies have revealed several critical regulatory mechanisms through which EZH2 suppresses immune response genes:

• Interferon Response Regulation:

  • IFNγ treatment increases H3K27me3 marks at approximately 3,773 genomic loci

  • EZH2 inhibition prevents this IFNγ-induced H3K27me3 deposition

  • 30% of genes that gain H3K27me3 with IFNγ also gain H3K27ac marks, suggesting complex regulatory dynamics

• MHC Class II Regulation:

  • EZH2 directly represses MHC Class II genes through H3K27me3 marks

  • Loss of H3K27me3 via EZH2 inhibition is necessary but not sufficient for MHC II expression

  • Full activation requires both EZH2 inhibition and IFNγ stimulation

• Pro-T Cell Cytokine Regulation:

  • The CXCL9/10/11 gene cluster shows a distinctive pattern:

    • IFNγ increases both H3K27me3 and H3K27ac marks

    • EZH2 inhibition reduces H3K27me3 while maintaining H3K27ac

    • This dual epigenetic modulation enhances gene expression

• Pro-Inflammatory Cytokine Suppression:

  • Some genes like IL1B are expressed in untreated cells

  • EZH2 inhibition paradoxically reduces their expression despite removing H3K27me3 marks

  • This suggests secondary regulatory mechanisms beyond direct EZH2-mediated repression

ChIP-seq data analysis revealed that of the 638 genes significantly upregulated by combined EZH2 inhibition and IFNγ treatment compared to IFNγ alone, 43% (274) showed a pattern of gaining H3K27me3 with IFNγ and losing these marks with combination treatment. These genes were enriched in pathways related to inflammatory responses, cell adhesion, TP53 signaling, and apoptosis .

How can EZH2 antibodies be used to evaluate the efficacy of EZH2 inhibitors in experimental models?

EZH2 antibodies serve as critical tools for evaluating the efficacy of EZH2 inhibitors in both in vitro and in vivo experimental models:

• Western Blot Analysis Protocol:

  • Harvest cells/tissues after treatment with EZH2 inhibitors (GSK126, EPZ6438, tazemetostat)

  • Prepare protein lysates using appropriate buffer systems

  • Separate proteins using SDS-PAGE (8-10% gels recommended for ~80 kDa EZH2)

  • Transfer to PVDF membrane and probe with anti-EZH2 antibody (1 μg/mL recommended)

  • Evaluate total EZH2 protein levels

  • Simultaneously assess H3K27me3 levels using specific antibodies as the functional readout of EZH2 inhibition

• Immunofluorescence/Immunohistochemistry Approach:

  • Fix cells/tissues using 4% paraformaldehyde

  • Perform antigen retrieval if necessary

  • Block and incubate with primary anti-EZH2 antibody

  • Detect using fluorescent or enzyme-conjugated secondary antibodies

  • Co-stain for H3K27me3 to correlate EZH2 presence with enzymatic activity

  • Analyze subcellular localization and expression patterns

• Functional Assessment Framework:

  • Combine EZH2 antibody detection with RNA-seq to correlate protein levels with transcriptional changes

  • Integrate with ChIP-seq data to map genome-wide effects of EZH2 inhibition

  • Use flow cytometry to measure downstream effects on target proteins (e.g., MHC I/II, PD-L1)

  • For in vivo models, correlate tumor control with EZH2 inhibition status as measured by antibody-based techniques

Research has demonstrated that effective EZH2 inhibition should result in:

• Minimal change in total EZH2 protein levels

• Significant reduction in global H3K27me3 levels

• Increased expression of previously repressed genes, particularly immune-related genes

• Enhanced cell surface expression of MHC molecules when combined with IFNγ treatment

What are common technical challenges when using EZH2 antibodies and how can they be addressed?

Researchers working with EZH2 antibodies frequently encounter several technical challenges that can be addressed using the following evidence-based approaches:

• Multiple Band Detection in Western Blot:

  • Challenge: Detection of bands at both 80-85 kDa and 100 kDa

  • Solution: Confirm specificity using knockout/knockdown controls; the 85 kDa band represents the calculated molecular weight of EZH2, while additional bands may represent post-translational modifications or splice variants

  • Validation: Compare band patterns across multiple antibody clones and in different cell types

• Variable Results Across Cell Lines:

  • Challenge: Inconsistent EZH2 detection or response to inhibitors

  • Solution: Test multiple cell lines (HeLa, Jurkat, A549) with known EZH2 expression; adjust exposure times or antibody concentrations based on baseline expression levels

  • Optimization: For low-expressing cells, consider using enhanced chemiluminescence substrates or more sensitive detection methods

• ChIP-seq Efficiency Issues:

  • Challenge: Poor enrichment or high background

  • Solution: Optimize crosslinking conditions specifically for EZH2; use H3K27me3 antibodies in parallel as functional readouts of EZH2 activity

  • Protocol Adjustment: Consider dual crosslinking with both formaldehyde and protein-specific crosslinkers

• 3D Culture Analysis Challenges:

  • Challenge: Difficulty in protein extraction from tumoroids

  • Solution: Extend treatment durations (9 days recommended) and modify sample processing protocols specifically for 3D cultures

  • Technical Adaptation: Include additional disaggregation steps before proceeding with standard antibody-based applications

How should experimental conditions be optimized when using EZH2 antibodies in combination with EZH2 inhibitors?

Optimizing experimental conditions is crucial when combining EZH2 antibodies with EZH2 inhibitors:

• Treatment Duration Optimization:

  • 2D Cultures: 5 days of EZH2 inhibitor followed by 2 days of inhibitor+IFNγ

  • 3D Cultures/Tumoroids: 9 days of EZH2 inhibitor followed by 2 days of inhibitor+IFNγ

  • Rationale: Longer duration allows for epigenetic reprogramming before cytokine stimulation

• Inhibitor Concentration Determination:

  • Recommended Approach: Perform dose-response curves with each inhibitor (GSK126, EPZ6438)

  • Functional Readout: Measure H3K27me3 levels via Western blot

  • Verification: Confirm that selected concentration achieves near-complete ablation of H3K27me3 marks in ChIP-seq analysis

• Timing for Antibody-Based Detection:

  • Western Blot/Flow Cytometry: 24-48 hours after final treatment

  • ChIP-seq: Immediately after treatment completion

  • Immunofluorescence: 24 hours post-treatment for optimal signal-to-background ratio

• IFNγ Concentration Standardization:

  • Starting Concentration: 100 ng/mL recommended based on research protocols

  • Validation Method: Confirm upregulation of known IFNγ-responsive genes like B2M and HLA-A

  • Synergy Measurement: Compare expression levels between IFNγ-only and EZH2i+IFNγ conditions

Research has shown that the combination of EZH2 inhibition and IFNγ produces synergistic effects on immune-related gene expression that neither treatment alone can achieve, emphasizing the importance of correctly timing and dosing both agents .

How might EZH2 antibodies contribute to developing improved cancer immunotherapy approaches?

EZH2 antibodies are instrumental in understanding mechanisms that could enhance cancer immunotherapy efficacy:

• Biomarker Development Applications:

  • EZH2 antibodies can detect expression levels that may predict response to immune checkpoint inhibitors

  • Tissues with high EZH2/H3K27me3 levels may benefit most from combination therapy with EZH2 inhibitors

  • Monitoring changes in EZH2 activity during treatment could serve as a pharmacodynamic marker

• Therapeutic Target Validation:

  • Research demonstrates that EZH2 inhibition enhances expression of MHC I/II molecules and pro-T cell cytokines

  • EZH2 antibodies can verify target engagement of EZH2 inhibitors in preclinical models

  • The observed upregulation of antigen presentation machinery suggests potential for improving T cell recognition of tumors

• Resistance Mechanism Identification:

  • EZH2 antibody-based ChIP-seq has revealed that IFNγ induces H3K27me3 at nearly 4,000 genomic loci

  • This suggests that EZH2 activity may contribute to resistance against IFNγ-mediated anti-tumor effects

  • Targeting this feedback mechanism could overcome resistance to immunotherapies

• Rational Combination Design:

  • Based on epigenetic profiling with EZH2 antibodies, rational combinations of:

    • EZH2 inhibitors (tazemetostat, GSK126, EPZ6438)

    • Immune checkpoint inhibitors (anti-PD1)

    • Cytokine therapy (IFNγ)

  • Could effectively reprogram the tumor immune microenvironment

Research in lung squamous cell carcinoma models has shown that EZH2 inhibition combined with anti-PD1 immunotherapy leads to strong tumor control in both autochthonous and syngeneic models, supporting the translational potential of these approaches .

What novel technological approaches are being developed to enhance EZH2 antibody applications in research?

Emerging technologies are expanding the utility of EZH2 antibodies in advanced research applications:

• Single-Cell Epigenomic Profiling:

  • Integration of EZH2 antibodies into single-cell CUT&Tag protocols

  • Allows mapping of H3K27me3 distribution at single-cell resolution

  • Enables identification of epigenetically distinct cell populations within heterogeneous tumors

• Proximity Labeling Methods:

  • Utilizing EZH2 antibodies conjugated to proximity labeling enzymes (BioID, APEX)

  • Identifies novel protein interactions in living cells

  • Helps map the dynamic composition of PRC2 complexes under different treatment conditions

• Spatial Epigenomics:

  • Combining EZH2 immunofluorescence with spatial transcriptomics

  • Correlates EZH2 activity with gene expression patterns in tissue context

  • Reveals microenvironmental influences on EZH2-mediated gene silencing

• Live-Cell Imaging Applications:

  • Development of intrabodies derived from conventional EZH2 antibodies

  • Enables real-time tracking of EZH2 dynamics during cell division and differentiation

  • Provides insights into temporal aspects of epigenetic reprogramming

• High-Throughput Screening Platforms:

  • Adaptation of EZH2 antibody-based assays for screening novel EZH2 modulators

  • Development of automated ChIP-seq protocols to accelerate epigenomic profiling

  • Integration with CRISPR screening to identify synthetic lethal interactions

These technological advances are positioned to transform our understanding of EZH2 biology and accelerate the development of epigenetic therapies for cancer and other diseases.